Evidence map›Paper›PMID 39198589›Full record

ArticlePediatric research2025

Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment.

Kathryn M Lemberg, Andrea M Gross, Lauren M Sproule, David J Liewehr, Eva Dombi, Andrea Baldwin, Seth M Steinberg, Miriam Bornhorst, Maya Lodish, Jaishri O Blakeley and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kathryn M LembergDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. klember1@jhmi.edu.ORCID 0000-0003-1511-9322
Andrea M GrossPediatric Oncology Branch, Center for Cancer Research, Bethesda, MD, USA.
Lauren M SprouleMcGill University, Montreal, QC, Canada.
David J LiewehrBiostatistics and Data Management Section, Center for Cancer Research, Bethesda, MD, USA.
Eva DombiPediatric Oncology Branch, Center for Cancer Research, Bethesda, MD, USA.
Andrea BaldwinClinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Seth M SteinbergBiostatistics and Data Management Section, Center for Cancer Research, Bethesda, MD, USA.
Miriam BornhorstGilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC, USA.
Maya LodishDivision of Pediatric Endocrinology, University of California San Francisco, San Francisco, CA, USA.
Jaishri O BlakeleyDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Brigitte C WidemannPediatric Oncology Branch, Center for Cancer Research, Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn children and adolescents/young adults (CAYA) with neurofibromatosis type I (NF1), associations between anthropometric measurements, plexiform neurofibroma (pNF) tumor volume (TV), and treatment history are unknown.

methodsWe retrospectively investigated anthropometrics in CAYA on the National Cancer Institute (NCI) NF1 Natural History Study who had pNF TV assessed by imaging (n = 106). We determined CDC height/weight percentiles and estimated Preece-Baines (PB) height growth curve parameters. We evaluated variables that could impact height/weight including: (1) pNF volume, (2) pNF directed therapy, and (3) serum IGF-1.

results23% of males and 20% of females had height <5th percentile; 13% of males had weight <5th percentile. Estimated median final adult height for males was 171.6 cm (CDC 23rd percentile) and for females was 156.2 cm (CDC 14th percentile). Inverse associations between height and weight percentiles and pNF volume were observed (Spearman's r = -0.277, -0.216, respectively). Estimated median final height was not meaningfully affected by patients who received pNF-directed treatment with MEK inhibitor. 52% of low serum IGF-1 measurements were concurrent with a height percentile <5th.

conclusionsGreater than expected percentages of patients had height/weight <5th percentile, and median final adult heights were <CDC 25th percentile. pNF volume was inversely associated with height/weight percentiles. IMPACT STATEMENT: Children and adolescents/young adults with neurofibromatosis type I (NF1) seen at a research hospital have lower height and weight percentiles than normative populations. Growth percentiles are inversely associated with plexiform neurofibroma tumor volumes and impacted little by MEKi treatment history in this subset of patients. These findings align with prior investigations of growth in the NF1 population but are the first to examine the association with tumor burden.

Indexed as

AnthropometryNeurofibroma, PlexiformNeurofibromatosis 1AdolescentBody HeightBody WeightChildChild, PreschoolFemaleHumansInsulin-Like Growth Factor IMaleRetrospective StudiesTumor BurdenYoung AdultIGF1 protein, humanInsulin-Like Growth Factor I

Identifiers

PMID39198589

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.